Form 4: Thermo Fisher COO Sells Shares for Tax Obligations

Thermo Fisher Scientific's Executive Vice President and COO, Michel Lagarde, disposed of 961.203 shares of common stock to cover tax liabilities.

Summary

• Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific Inc. (TMO), reported changes in beneficial ownership.
• On August 28, 2025, Lagarde disposed of a total of 961.203 shares of common stock across four separate transactions.
• The dispositions were made at a price of $489.74 per share.
• These transactions were coded 'F,' indicating they were for the payment of tax liability by delivering or withholding securities.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up a pre-scheduled plan for buying or selling company stock.
• Following these transactions, Lagarde beneficially owns 23,479.909 shares of common stock directly.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine disposition of shares for tax purposes by an executive, executed under a pre-arranged plan, and does not indicate a change in company fundamentals or executive sentiment.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1(c) plan, indicating a planned disposition rather than an immediate reaction to market conditions or new information.

Negatives

• The disposition of shares by a key executive reduces their direct equity stake in the company, although this is a routine event for tax purposes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction for tax purposes and does not provide broader industry insights or indicate specific trends within the life sciences or healthcare technology sectors.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but generally considered a routine tax-related event with minimal impact on shareholder confidence.
• Employees: No direct impact on employees.

Key Dates

Recommendation

The reported transaction is a routine disposition of shares by an executive to cover tax obligations, executed under a pre-arranged 10b5-1 plan. This type of transaction is common and does not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Thermo Fisher Scientific, TMO, Michel Lagarde, Insider Trading, Form 4, Stock Sale, Executive Compensation, Tax Liability, Rule 10b5-1